



EUROPEAN  
HEMATOLOGY  
ASSOCIATION

  
Journal of the European Hematology Association

## Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

by Anders Österborg, Roxanne C. Jewell, Swami Padmanabhan-Iyer, Thomas J. Kipps, Jirí Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Richard R. Furman, Tadeusz Robak, Peter Hillmenn, Marek Trnený, Martin J.S. Dyer, Magdalena Piotrowska, Tomas Kozak, Ira V. Gupta, Jennifer L. Phillips, Nancy Goldstein, Herbert Struemper, Nedjad Losic, Steen Lisby, and William G. Wierda

Haematologica 2015 [Epub ahead of print]

*Citation: Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmenn P, Trnený M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, and Wierda WG . Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.*

*Haematologica. 2015; 100:xxx*

*doi:10.3324/haematol.2014.121459*

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.*

## **Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study**

Anders Österborg,<sup>1</sup> Roxanne C. Jewell,<sup>2</sup> Swami Padmanabhan-Iyer,<sup>3</sup> Thomas J. Kipps,<sup>4</sup> Jiří Mayer,<sup>5</sup> Stephan Stilgenbauer,<sup>6</sup> Cathy D. Williams,<sup>7</sup> Andrzej Hellmann,<sup>8</sup> Richard R. Furman,<sup>9</sup> Tadeusz Robak,<sup>10</sup> Peter Hillmen,<sup>11</sup> Marek Trněný,<sup>12</sup> Martin J.S. Dyer,<sup>13</sup> Magdalena Piotrowska,<sup>14</sup> Tomas Kozak,<sup>15</sup> Ira V. Gupta,<sup>16</sup> Jennifer L. Phillips,<sup>16</sup> Nancy Goldstein,<sup>2</sup> Herbert Struemper,<sup>2</sup> Nedjad Losic,<sup>17</sup> Steen Lisby,<sup>17</sup> and William G. Wierda<sup>18</sup> for the Hx-CD20-406 Study  
Investigators

<sup>1</sup>Department of Hematology, Karolinska University Hospital, Stockholm, Sweden;

<sup>2</sup>GlaxoSmithKline, Research Triangle Park, NC, USA;

<sup>3</sup>Cancer Therapy Research Center, San Antonio, TX, USA (formerly Roswell Park Cancer Institute, Buffalo, NY, USA);

<sup>4</sup>UCSD Moores Cancer Center, La Jolla, CA, USA;

<sup>5</sup>Faculty Hospital Brno, Dept of Internal Medicine/Hemato-Oncology, Brno, Czech Republic;

<sup>6</sup>Universitätsklinikum Ulm, Department of Internal Medicine III, Ulm, Germany;

<sup>7</sup>Center for Clinical Haematology, Nottingham University Hospitals, Nottingham, UK;

<sup>8</sup>Department of Hematology, Medical University of Gdansk, Gdansk, Poland;

<sup>9</sup>Weill Cornell Medical College, Division of Hematology/Oncology, New York, NY, USA;

<sup>10</sup>Department of Hematology, Medical University of Lodz, Lodz, Poland;

<sup>11</sup>St James' Institute of Oncology, St James' University Hospital, Leeds, UK;

<sup>12</sup>First Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic;

<sup>13</sup>The Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK;

<sup>14</sup>Klinika Hematologii CMUJ, Krakow, Poland;

<sup>15</sup>University Hospital Kralovske Vinohrady, Department of Clinical Hematology, Prague, Czech Republic;

<sup>16</sup>GlaxoSmithKline, Collegeville, PA, USA;

<sup>17</sup>Genmab, Copenhagen, Denmark;

<sup>18</sup>The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

**Running title:** Ofatumumab in fludarabine-refractory CLL

**Correspondence:** Anders Österborg, M.D., Ph.D., Department of Hematology, Karolinska University Hospital Solna, Stockholm, SE-17176, Sweden; email: anders.osterborg@karolinska.se

**Trial registration:** [clinicaltrials.gov](https://clinicaltrials.gov) identifier NCT000349349

### **Acknowledgments**

The authors would like to thank the patients and the investigators in the Hx-CD20-406 Study for their participation in the study as well as the members of the IRC for their review. This study was supported by Genmab and GlaxoSmithKline.

While fludarabine-based regimens are a standard for treatment of chronic lymphocytic leukemia (CLL), patients who become refractory to fludarabine have had low response rates with salvage therapy and poor survival outcomes (1-3). We reported that ofatumumab, a human monoclonal antibody that binds to a distinct epitope of the CD20 molecule on B cells (4), was effective as monotherapy for fludarabine-refractory CLL at the interim analysis (5). Here we report the final analysis of the study, including a landmark analysis demonstrating clinical benefit in patients who responded and the results of pharmacokinetic analyses and of exploratory analyses to identify factors associated with ofatumumab pharmacokinetics and clinical outcomes.

The study design and patient selection criteria were previously reported (5). Patients were required to be refractory to at least one fludarabine-containing regimen and either refractory to at least one alemtuzumab-containing regimen (FA-ref) or considered unsuitable for alemtuzumab due to bulky (>5 cm) lymphadenopathy (BF-ref) and were assigned to the population subgroups by the Independent Review Committee (IRC).

All patients were to receive eight weekly intravenous infusions of ofatumumab, followed by four monthly infusions (Dose 1: 300 mg; Doses 2–12: 2000 mg). Of the 223 patients, 89% received all 8 weekly infusions, and 51% of patients received all 12 infusions.

The primary endpoint was objective response rate (ORR) assessed by the IRC using the 1996 NCI-WG criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), pharmacokinetics, and adverse events (AEs).

The efficacy observed in the final analysis confirmed the results of the previous interim analysis (5). Responses were rapid and consistent across subgroups (Table 1). The response rate and the lower bound of the 95% CI for ORR exceeded the pre-planned null hypothesis response rate of 15% ( $p < 0.001$  in both groups).

Response rates were not significantly different between patient groups by demographics, prior CLL therapy, disease characteristics, chromosomal abnormalities, CD38 status, and Fc receptor polymorphism, with the exception of patients with 17p deletion who had a lower response rate (30%) than patients without 17p deletion (53%;  $p=0.0055$ ).

Ofatumumab demonstrated significant benefit in responders. Most responses had occurred by Week 12; on the basis of a landmark analysis (6, 7) starting at Week 12 (Figure 1A and Figure 1B), median OS was significantly longer among responding patients compared with non-responding patients (FA-ref: 24.9 months v. 9.9 months [ $p=0.0003$ , log rank test] and BF-ref: 28.9 months v. 15.5 months [ $p=0.0154$ ]). This significantly longer survival among responders compared to non-responders indicated that achievement of a partial remission is an important goal and confers meaningful clinical benefit in patients with CLL, even heavily pretreated CLL.

Similar to the interim analysis, the final analysis showed that ofatumumab was well tolerated with no unexpected toxicities and no formation of anti-ofatumumab antibodies. Infusion-related reactions were mostly Grade 1-2 and occurred predominantly during the first and second infusion, decreasing from 43% at the first infusion to 6% at the final (twelfth) infusion. Only 30 patients (13%) discontinued ofatumumab early due to AE.

Overall, 24% of patients had at least one Grade 3 or 4 infection (Table 1). Major infections (leading to hospitalization for >48 hours during or within four weeks of completing treatment) occurred in 64 (29%) patients. Analysis of infections by CLL risk factors suggested that underlying disease was the major risk factor for infections  $\geq$  Grade 3. Twenty infections during treatment (9% of patients) led to death. Other causes of death during treatment or follow-up were neutropenia ( $n=1$ ), disease progression ( $n=1$ ), cardiovascular events ( $n=4$ ), and pulmonary edema/respiratory failure ( $n=1$ ).

Cytopenias appeared to be mainly related to the underlying disease, given that improvements in median hemoglobin and platelet levels were observed and median neutrophil counts remained in the normal range during the study.

Ofatumumab pharmacokinetic analysis was performed using a population approach with a two-compartment model with an additional estimated target-mediated clearance component to describe the effect of B-cell binding on ofatumumab pharmacokinetics using NONMEM VI (ICON, Ellicott City, MD). The development and performance characteristics of the model have been described (8). Serum ofatumumab concentrations for pharmacokinetic analysis were determined using a validated ELISA with a lower limit of quantification of 0.1 µg/mL described previously (9).

Pharmacokinetic parameter values were comparable among the FA-ref, BF-ref, and Other groups (data not shown), and all summaries and analyses combined pharmacokinetic data from the three patient groups (Table 2). The geometric mean clearance, volume of distribution at steady state, and half-life values after the eighth or twelfth infusion were approximately 12 mL/h, 4 to 5 L, and 12 to 14 days. These pharmacokinetic parameter values are similar to those reported previously in patients with CLL (10, 11).

Demographic and disease factors at baseline associated with ofatumumab pharmacokinetic parameter values were identified by exploratory univariable and multivariable regression analyses. The factors identified as potentially significant ( $p < 0.10$ ) in univariable analyses were combined in a multivariable analysis, and factors were removed by backward elimination with retention in the final model at  $p < 0.05$ . Relationships between clinical outcome measures (OR, PFS, and OS) and the same patient and disease factors at baseline as well as ofatumumab exposure measures ( $C_{max}$ ,  $C_{trough}$ , and AUC at Doses 1, 8, and 12) were

evaluated by exploratory logistic regression analyses (OR) or Cox regression analyses (PFS and OS).

In multivariable analyses, higher C<sub>max</sub> values at the first infusion were associated with smaller body surface area, lower percentage of marrow involvement, lower baseline lymphocyte count, lower Rai stage, and lower  $\beta_2$ -microglobulin. Ofatumumab exposure measures (C<sub>max</sub>, C<sub>trough</sub>, and AUC) at Dose 8 were higher in female patients than in male patients and were lower in patients with higher baseline  $\beta_2$ -microglobulin; C<sub>max</sub> and AUC values were lower in patients with higher percentages of CLL marrow involvement and higher baseline total IgG concentrations. Higher percentages of marrow involvement, IgG concentrations,  $\beta_2$ -microglobulin, and body surface area were associated with higher ofatumumab clearance values at Dose 8, while female subjects had lower clearance values. The results of this analysis demonstrate an association between ofatumumab pharmacokinetic parameter values and baseline factors reflecting disease burden, gender, and body surface area.

These findings are consistent with current understanding of the mechanisms involved in the clearance of ofatumumab. Like other IgG antibodies, ofatumumab is cleared via uptake into cells of the reticuloendothelial system and catabolism by ubiquitous proteolytic enzymes, a mechanism that not saturated by administration of typical doses of therapeutic monoclonal antibodies. In addition, ofatumumab is cleared by binding to the CD20 epitope on B cells (target-mediated clearance). The observed associations of ofatumumab pharmacokinetics with measures of disease burden at baseline are consistent with a large contribution of target-mediated clearance to ofatumumab total clearance at high B-cell counts and high B-cell input rates. The association of exposure with gender and/or body surface area is consistent with distribution of monoclonal antibodies largely in the systemic circulation.

Based on univariable analyses, higher C<sub>max</sub>, C<sub>trough</sub>, and AUC(0-∞) values at Dose 8 were associated with objective response (OR); ofatumumab C<sub>max</sub>, C<sub>trough</sub>, and AUC values at Dose 1, Dose 8, and Dose 12 were significantly associated with PFS, with higher exposure at all three infusions associated with longer PFS; and higher C<sub>max</sub> and C<sub>trough</sub> values at Dose 8 were associated with longer OS. In multivariable analyses including ofatumumab pharmacokinetic parameter values as well as demographic and baseline characteristics, ofatumumab pharmacokinetic parameter values were not retained in the final models for OR, PFS, or OS. For OR, clinical disease factors (β<sub>2</sub>-microglobulin concentration, number of lymph nodes, and 17p deletion) were the significant factors. Disease and patient factors (β<sub>2</sub>-microglobulin concentration, thymidine concentration, age ≥75 years, and lymph node size) were the significant factors associated with PFS in multivariable analysis. For OS, disease and patient factors (β<sub>2</sub>-microglobulin concentration, thymidine concentration, lymph node size, ECOG status, and platelet counts) were the significant factors. These results showed that measures of disease burden at baseline and patient factors, rather than ofatumumab exposure, were associated with clinical outcomes.

Based on the relationship between disease burden and ofatumumab clearance, patients with a high disease burden (B-cell mass) may benefit from high ofatumumab dose intensity, particularly early in treatment. Patients with highly refractory CLL, as in this study, may benefit from high and frequent individual doses early in therapy to elicit response and a long duration of dosing to maintain response. Responses persisted for a median of less than three months after the last dose of ofatumumab, and early progression after cessation of treatment provides support for the suggestion that patients with refractory CLL may benefit from a longer duration of dosing. This is further supported from two recently presented phase 3 trials (12, 13) While ofatumumab



as standard-length monotherapy was inferior to continuous ibrutinib treatment in a recent comparative study (14), it remains a therapeutic option for patients who relapse after treatment with kinase inhibitors.

In summary, this final analysis of the pivotal trial in fludarabine-refractory CLL demonstrates that ofatumumab provides meaningful clinical benefit for difficult-to-treat CLL patient groups and warrants further investigation in earlier disease settings, with longer-term administration, and in combination with drugs having different mechanisms of action, including targeted therapies such as ibrutinib and idelalisib.

#### AUTHORSHIP:

**Contribution:** A.O., P.H., N.L., S.L., and W.G.W. conceived and designed the research; A.O., S.P.-I., T.J.K., J.M., S.S., C.D.W., A.H., R.R.F., T.R., P.H., M.T., M.J.S.D., M.P., T.K., and W.G.W. performed the research; A.O., R.C.J., T.J.K., S.S., C.D.W., R.R.F., T.R., M.T., M.J.S.D., I.V.G., J.L.P., N.G., H.S., N.L., W.G.W. analyzed and interpreted the results; A.O., R.C.J., T.J.K., S.S., C.D.W., A.H., R.R.F., T.R., P.H., I.V.G., J.L.P., N.G., H.S., N.L., S.L., and W.G.W. wrote and reviewed the manuscript; A.O., R.C.J., S. P.-I., T.J.K., J.M., S.S., C.D.W., A.H., R.R.F., T.R., P.H., M.T., M.J.S.D., M.P., T.K., I.V.G., J.L.P., N.G., H.S., N.L., S.L., and W.G.W. approved the manuscript.

**Conflict-of-interest disclosure:** R.C.J., I.V.G., J.L.P., N.G., H.S., N.L., and S.L. are employed by and have an ownership stake in Genmab or GlaxoSmithKline; A.O., J.M., S.S., T.R., and P.H. received research funding from Genmab or GlaxoSmithKline; A.O., S.S., P.H., T.K., and W.G.W. received honoraria from Genmab or GlaxoSmithKline; N.L. is a member of the board of

directors of Genmab; S. P.-I., T.J.K., C.D.W., A.H., M.T., M.J.S.D., and M.P. declare no competing financial interests.

## REFERENCES

1. Eketorp Sylvan S, Hansson L, Karlsson C, Norin S, Lundin J, Osterborg A. Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. *Leuk Lymphoma*. 2014; 55(8):1774-1780.
2. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. *Leuk Lymphoma*. 2002; 43(9):1755-1762.
3. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. *Leuk Lymphoma*. 2007; 48(10):1931-1939.
4. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. *J Immunol*. 2006; 177(1):362-371.
5. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol*. 2010; 28(10):1749-1755.
6. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. *J Clin Oncol*. 1983;1(11):710-719.
7. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. *J Clin Oncol*. 2008; 26(24):3913-3915.
8. Struemper H, Sale M, Patel BR, et al. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. *J Clin Pharmacol*. 2014; 54(7):818-827.
9. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. *Blood*. 2008; 111(12):5486-5495.
10. Coiffier B, Losic N, Ronn BB, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. *Br J Haematol*. 2010; 150(1):58-71.
11. Österborg A, Ronn BB, Jewell RC, et al. Correlation between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab. *Blood (ASH Annual Meeting, Abstract 3433)*. 2009; 114(22).
12. van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results. *Blood (ASH Annual Meeting Abstracts)*. 2014; 124(21).
13. Österborg A, Udvardy M, Zaritskey A, et al. Ofatumumab (OFA) Vs. Physician's Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242. *Blood (ASH Annual Meeting, Abstract 4684)*. 2014; 124(21).
14. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014; 371(3):213-223.

**Table 1 Overview of Updated Efficacy Outcomes and Adverse Events During Treatment and Follow-Up to 24 Months**

	<b>FA-ref (N=95)</b>	<b>BF-ref (N=112)</b>
<b>Efficacy Endpoint</b>		
ORR, %	49	43
95.3% CI	39, 60	33, 53
Duration of Response (months), median	5.5*	6.4 <sup>†</sup>
Duration of Response after Last Infusion (months), median	2.3*	2.5 <sup>†</sup>
PFS (months), median	4.6	5.5
OS (months), median	13.9	17.4
<b>Safety Results</b>		
Any AE	90 (95)	107 (96)
AEs Grade $\geq$ 3	67 (71)	60 (54)
Any AE leading to withdrawal from treatment	15 (16)	13 (12)
Non-fatal SAEs	53 (56)	55 (49)
Fatal (Grade 5) SAEs	20 (21)	17 (15)
Infusion-related AEs	79 (83)	87 (78)
Infection AEs	72 (76)	77 (69)

Abbreviations: ORR, overall response rate; OS, overall survival; PFS, progression-free survival

\* n = 47

<sup>†</sup> n = 48

**Table 2 Summary of Ofatumumab Pharmacokinetic Parameter Values**


Parameter	n	Infusion 1 (300 mg)	n	Infusion 8 (2000 mg)	n	Infusion 12 (2000 mg)
C <sub>max</sub> (µg/mL)	215	61.4 (73)	193	1391 (46)	106	827 (41)
C <sub>trough</sub> (µg/mL)	-	-	192	549 (234)	106	32.1 (5883)
AUC(0-τ) <sup>*</sup> (µg.h/mL)	-	-	163	171286 (48)	84	165617 (123)
AUC(0-∞) (µg.h/mL)	-	-	133	463418 (94)	83	203536 (164)
CL (mL/h)	-	-	163	11.7 (48)	84	12.1 (123)
V <sub>ss</sub> (L)	-	-	133	4.84 (30)	83	3.73 (30)
t <sub>1/2</sub> (days)	-	-	141	13.6 (56)	81	11.5 (87)

Data are presented as geometric mean (% coefficient of variation). Abbreviations: C<sub>max</sub>, maximum observed concentration; C<sub>trough</sub>, observed concentration prior to next infusion; AUC(0-τ), area under the concentration-time curve over the dosing interval τ; AUC(0-∞), area under the concentration-time curve extrapolated to infinity; CL, clearance; V<sub>ss</sub>, volume of distribution at steady state; t<sub>1/2</sub>, half-life.

\* τ = 168 h at Infusion 8 and 672 h at Infusion 12


## **FIGURE LEGEND**

**Figure 1: Kaplan-Meyer Curves for Overall Survival; Landmark Analysis.** (A) By Response in Week 12 Survivors in FA-ref group. (B) By Response in Week 12 Survivors in BF-ref Group.



Number of Subjects at Risk:

Responder	43	42	40	39	34	32	31	28	26	25	21	19	15	14	12	10	7	3	2	2	1	1	1	0
Non-Responder	41	33	28	22	18	17	12	9	7	7	6	5	5	3	3	3	1	0	0	0	0	0	0	0



Number of Subjects at Risk:

Responder	41	41	39	35	34	31	30	26	26	24	22	20	17	15	13	11	6	3	1	1	1	1	0	0
Non-Responder	64	61	55	47	40	35	33	27	20	19	18	15	11	10	8	5	3	1	1	0	0	0	0	0